LEO Pharma is expanding access to early and growth-stage dermatology related businesses with an investment via the Strategic Investment Programme of healthcare-focussed venture capital firm Gore Range.
Gore Range is partnering with LEO Pharma’s senior management to invest in companies and projects of mutual interest.
Beyond capital, portfolio companies will benefit from LEO Pharma’s industry expertise and strong R&D capabilities and Gore Range’s experience in nurturing new enterprises.
“The dermatology arena has tremendous potential and we will be at the forefront of providing value to our partners by driving new and better treatment options for patients,” said Gore Range Partner Humberto Antunes.
Thorsen Thormann, Vice President, Research at LEO Pharma, added: “We partnered with Gore Range to access cutting-edge, emerging companies by leveraging their robust deal flow, stringent due diligence, and proven ability to oversee and actively manage their portfolio companies.”
Ethan Rigel, partner and CEO of Gore Range, said: “Our experience has been that early and growth-stage companies can really flourish when they have a partner who brings resources and provides guidance and access to relationships that move their businesses from idea to execution.
“Our work together with LEO Pharma is an example of the approach we are taking that will make a meaningful difference for our portfolio companies. They are an ideal partner for our Strategic Investor Program.”